Life Science Intermediates Market Consolidation: Who will not survive?
- Will the industry consolidate, decentralize, or undergo a bimodal transformation?
- How will the current trends affect the major market segments?
- Which companies will enter the market and which will not survive?
- Internally developed and acquired technologies, and related capabilities.
- Proprietary technologies and patent litigations.
Contains 35 pages
1. BASF
2. CAMBREX
3. CLARIANT
4. DOWPHARMA
5. DSM
6. EVONIK
7. LANXESS
8. LONZA
9. NOVASEP
10. RHODIA
FOR EACH COMPANY, THE REPORT PRESENTS:
Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.
2. CAMBREX
3. CLARIANT
4. DOWPHARMA
5. DSM
6. EVONIK
7. LANXESS
8. LONZA
9. NOVASEP
10. RHODIA
FOR EACH COMPANY, THE REPORT PRESENTS:
Internally developed and acquired technologies, and related capabilities.
Proprietary technologies and patent litigations.
More Publications
Animal Health Market Consolidation 2017-2022 : Who will not survive?
US$ 4,850.00
January 2018
110 pages
CompetitiveWatch 2015: Leading Food and Beverage Suppliers' Marketing Tactics and Strategic Directions
US$ 1,960.00
June 2015
-
Competitive Intelligence 2014: Global Flavor and Fragrance Market Outlook and Leading Suppliers' Strategies, Marketing Tactics, and Technological Know-How
US$ 3,880.00
March 2014
154 pages
Paint and Coatings Market Consolidation 2017-2022: Who will not survive?
US$ 4,850.00
January 2018
142 pages
